Venlo, the Netherlands, June 15, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) welcomes the publication of a new, systematic review highlighting the unique value of its ...
At its J.P. Morgan Healthcare Conference 2026 presentation, Qiagen NV alluded to positive full-year results for 2025 and ...
QIAGEN QGEN recently reached a major landmark in the field of tuberculosis (TB) testing. On World TB Day, the company announced that since the lime of its launch, the company’s QuantiFERON blood test ...
QuantiFERON SARS-CoV-2 assay launched in December 2021 now CE-marked for clinical use measuring SARS-CoV-2 T-cell responses QuantiFERON-TB Gold Plus assay for TB detection set to benefit from three ...
VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the German Federal Patent Court (Bundespatentgericht) has ruled in its favor in a ...
HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the launch of its QuantiFERON SARS-CoV-2 RUO solution that can detect ...
To describe the use of the second-generation QuantiFERON-TB Gold (QFT-G) test in a series of patients in an ophthalmic practice. The charts of all patients who had QFT-G tests ordered by Mayo Clinic ...
QuantiFERON TB (QFT) was the first interferon gamma release assay (IGRA) utilizing whole blood stimulation as a test for TB infection, gaining FDA approval in 2001. Subsequently there have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback